Viral Vectors & Plasmid DNA Manufacturing Market Revenue to Attain USD 23.70 Bn by 2033

06 Jan 2025

Share :

Table of Content

1. Viral Vectors & Plasmid DNA Manufacturing Market Revenue and Trends 2024 to 2033 2. Market Overview 3. Report Highlights of the Viral Vectors & Plasmid DNA Manufacturing Market  4. Major Trends in the Viral Vectors & Plasmid DNA Manufacturing Market 5. Regional Insights 6. Viral Vectors & Plasmid DNA Manufacturing Market Coverage 7. Market News 8. Viral Vectors & Plasmid DNA Manufacturing Market Key Players

Viral Vectors & Plasmid DNA Manufacturing Market Revenue and Trends 2024 to 2033

The global viral vectors & plasmid DNA manufacturing market revenue is estimated to surpass around USD 23.70 billion by 2033 increasing from USD 6.26 billion in 2024, growing at a CAGR of 15.59%. Increasing advancements in gene therapy and manufacturing processes to produce viral vectors and plasmid DNA is expected to propel the market for viral vectors & plasmid DNA manufacturing during the forecast period.

Market Overview

Viral vectors are mostly used as carriers for transforming genetic materials into living organisms. They can be produced in two types of culture systems: adherent cell systems and suspension cell cultures. Plasmid DNA is extrachromosomal DNA, which is found in bacteria and is mostly used to create recombinant DNA to transfer genetic material to other organisms. The rising incidences of genetic disorders and infectious diseases are boosting the growth of the market. Moreover, the rising partnerships and collaborations among key players and healthcare organizations to increase the production of viral vectors and plasmid DNA and the increasing investments in research and development for gene therapies contribute to market expansion.

Report Highlights of the Viral Vectors & Plasmid DNA Manufacturing Market 

• By vector type, the AAV segment dominated the market with the largest share in 2024 due to the increased demand for gene therapies. The adeno-associated virus (AVV) vectors are most popular for delivering genes and treating various illnesses. They find applications in cell-based gene therapies.
• By application, gene therapy and antisense & RNAi emerged as dominating segments in 2024. This is mainly due to the increased use of viral vectors and plasmid DNA in the development of gene therapies and vaccines. The small interfering RNAs are an important tool for post-transcriptional gene silencing through genetic analysis of cells.
• By workflow, the downstream processing segment held the largest share of the market in 2024 due to its complex procedures for polishing and purifying clinical-grade final products.
• By end-user, the biopharmaceutical & pharmaceutical companies accounted for the largest share of the market in 2024. This is mainly due to a significant increase in the number of gene therapy research programs by these companies. Moreover, the increased use of viral vectors for therapeutic production contributed to the growth of the segment.
• By disease, the cancer segment dominated the market for viral vectors & plasmid DNA manufacturing with the largest share in 2024. This is mainly due to the increased cases of cancer worldwide. In addition, a significant rise in the demand for gene therapies to treat cancer propelled the segment.

Major Trends in the Viral Vectors & Plasmid DNA Manufacturing Market

• Rising Demand for Gene Therapies: With the increasing prevalence of cancer, cystic fibrosis, heart diseases, diabetes, hemophilia, and AIDS, there is a high demand for gene therapies to treat these diseases, which boosts the growth of the market. Viral vectors are widely used in gene therapy delivery due to their high efficacy. In addition, the rising clinical trials on viral vectors and plasmid DNA manufacturing and rising investments to boost the production of gene therapies contribute to market growth.
• Technological Advancements: Ongoing technological advancements positively impact the market. Innovations in manufacturing processes enhance the quality of viral vectors and increase yields. Key players operating in the market are also making efforts to launch advanced manufacturing technologies to improve the production of viral vectors and plasmid DNA, contributing to market expansion.
• Increasing Production of DNA Vaccines: With the increasing demand for personalized therapies, the production of DNA vaccines is rising significantly. However, plasmid DNA plays a key role in manufacturing DNA vaccines.

Regional Insights

North America dominated the viral vectors & plasmid DNA manufacturing market with the largest share in 2024. This is mainly due to the increased investments in research and development of gene and cell therapies. The region also boasts many contract development organizations and pharmaceutical and biotechnology companies, further bolstering the market in the region. On the other hand, Asia Pacific is expected to witness the fastest growth in the market in the coming years. This is primarily due to the increasing development of gene therapies and DNA vaccines. Moreover, there is a high demand for targeted and personalized therapies due to the rising prevalence of cancer, contributing to regional market expansion.

Viral Vectors & Plasmid DNA Manufacturing Market Coverage

Market News

• In May 2024, Charles River Laboratories International announced the launch of a modular and fast-track viral vector technology transfer framework that offers phase-appropriate and customizable frameworks to yield exceptional stability, helping to avoid costly and time-consuming program delays.
• In March 2024, Polyplus announced the launch of pPLUS AAV-RC2, a plasmid tailored for the production of adeno-associated virus vector 2, which is designed to streamline the manufacturing process, offering a ready-to-use solution that enhances both efficiency and reliability in vector production.

Viral Vectors & Plasmid DNA Manufacturing Market Key Players

• Novasep
• Aldevron
• MerckWaismanBiomanufacturing
• Creative Biogene
• The Cell and Gene Therapy Catapult
• Cobra Biologics
• uniQure N.V.
• Addgene
• FUJIFILM Holdings Corporation
• Oxford Biomedicaplc
• Takara Bio Inc.

Market Segmentation

By Vector Type

• Adenovirus
• Plasmid DNA
• Lentivirus
• Retrovirus
• AAV
• Others

By Application

• Gene Therapy
• Antisense &RNAi
• Cell Therapy
• Vaccinology

By Workflow

• Upstream Processing
• Vector Recovery/Harvesting
• Vector Amplification & Expansion
• Downstream Processing
• Fill-finish
• Purification

By End-User

• Biopharmaceutical and Pharmaceutical Companies
• Research Institutes

By Disease

• Genetic Disorders
• Cancer
• Infectious Diseases
• Others

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview@ https://www.precedenceresearch.com/checkout/1012

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 804 441 9344